Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387582 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema
A Phase 2 study of Diabetic Macular Edema and Diabetic Retinopathy, sponsored by Rocky Mountain Retina Consultants.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT00387582 is a Phase 2 study of Diabetic Macular Edema and Diabetic Retinopathy that has completed, run by Rocky Mountain Retina Consultants. The registered enrollment target is 49 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00387582, a Phase 2 study of Diabetic Macular Edema and Diabetic Retinopathy, has completed, sponsored by Rocky Mountain Retina Consultants.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the clinical efficacy of intra-vitreal injections of Ranibizumab (Lucentis) in the treatment of Diabetic Macular Edema as compared to grid/focal laser.
Conditions Studied
Interventions
- DRUG Ranibizumab (Lucentis)
- PROCEDURE Argon Laser
Study Locations (1)
Utah
- Rocky Mountain Retina Consultants - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387582
The ClinicalTrials.gov registry entry for NCT00387582 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The listed sponsor is Rocky Mountain Retina Consultants, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Ranibizumab (Lucentis) is the first listed.
NCT00387582 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT00387582 about?
NCT00387582 is a clinical study titled "Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema". This study will evaluate the clinical efficacy of intra-vitreal injections of Ranibizumab (Lucentis) in the treatment of Diabetic Macular Edema as compared to grid/focal laser.
What is the current status of trial NCT00387582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2006-07. Estimated completion is 2009-02.
What conditions does trial NCT00387582 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Diabetic Retinopathy.
What interventions are being tested in trial NCT00387582?
The interventions under investigation include: Ranibizumab (Lucentis) (DRUG), Argon Laser (PROCEDURE).
Who is sponsoring clinical trial NCT00387582?
This trial is sponsored by Rocky Mountain Retina Consultants, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00387582 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
RECRUITING · Phase 2
-
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
ACTIVE NOT RECRUITING · Phase 2
-
4D-150 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Tonabersat for DME
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.